key: cord-0934679-fvzykt6r
authors: Malsy, Jakob; Veletzky, Luzia; Heide, Janna; Hennigs, Annette; Gil-Ibanez, Ines; Stein, Alexander; Lütgehetmann, Marc; Rosien, Ulrich; Jasper, Dorothea; Peine, Sven; Hiller, Jens; Haag, Friedrich; Schmiedel, Stefan; Huber, Samuel; Jordan, Sabine; Addo, Marylyn M; Schulze zur Wiesch, Julian
title: Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
date: 2020-10-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1637
sha: e12e90c5033922f5fcdd59c74040160a60ecb0d2
doc_id: 934679
cord_uid: fvzykt6r

We provide detailed clinical, virological and immunological data of a B-cell depleted patient treated with obinutuzumab for follicular lymphoma with protracted COVID-19 and viremia. A sustained response was achieved after two courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

The majority of patients with coronavirus disease 2019 show mild to moderate symptoms, while a minority develops a more severe disease course that can include complications like ARDS, septic shock, cardiac injury and thrombosis [1, 2] . Immunocompromised patients are prone to prolonged disease courses, but at the same time might be protected from severe disease mediated by an overstimulation of the immune system [3, 4] . First case reports of COVID-19 patients with B-cell depletion after anti-CD20 therapy seem to confirm this notion [5, 6] . The nucleotide analogue remdesivir is the only antiviral agent approved for the treatment of COVID-19 to date and the efficacy of convalescent plasma therapy is currently being assessed [7] . Here, we report about a prolonged COVID-19 course with SARS-CoV-2 viremia in a patient who received the CD20 + cell depleting antibody obinutuzumab after chemotherapy for follicular lymphoma prior to infection with SARS-CoV-2. This patient did not produce SARS-CoV-2-specific antibodies and did not clear viremia on her own despite the detection of SARS-CoV-2-specific T-cells. After subsequent combination therapy with remdesivir and convalescent plasma, this patient now displays a sustained virological control of COVID-19.

On March 23, 2020 a 53-year-old woman returned from a ski trip and presented to our emergency department with recurrent fever, myalgias, asthenia, loss of appetite, a dry cough and mild dyspnea. A nasopharyngeal swab had tested positive for SARS-CoV-2 RNA (Fig.1) . In 2019 the patient had been treated with obinutuzumab-CHOP for a follicular lymphoma (grade I, Ki67 40%, stage III). Starting November 2019, she received monotherapy with obinutuzumab (last dose in January 2020, 1000mg i.v.). On admission, the results of her physical exam were as follows: body temperature 37.8° Celsius, blood pressure 120/60 mm Hg, heart rate 89 beats per minute, respiratory rate of 14 breaths per minute and oxygen saturation of 98% while breathing ambient air. A chest radiograph showed faint patchy consolidations in the lower lungs. Laboratory findings included anemia (Hb 11.8 g/dl), leukocytopenia (2.4 x 10 9 /l), and lymphocytopenia (0.48 x 10 9 /l). CRP, LDH and IL-6 were elevated with 26 mg/l, 284 U/l and 26.6 ng/l respectively, B-cells were undetectable and T-cell counts were low (374 /μl). Both CD4 + and CD8 + T-cell numbers were decreased (293 /μl and 61 /μl respectively) with a CD4 + /CD8 + ratio of 4.78 and a normal concentration of regulatory T-cells (8.4 %) (Fig.1A, Tab.1) .

The patient was discharged following the resolution of her fever and improvement of asthenia and myalgias after one week. However, she was readmitted after two days with renewed fever, nausea, progressive dyspnea and unchanged elevated laboratory parameters (Tab.1). Regularly collected nasopharyngeal swabs were negative since day 21 after the onset of symptoms. Hereafter, the sputum remained positive. A CT-scan on day 35 revealed a progression of the infection from the upper to the lower airways with detection of bilobular pulmonary infiltrations ( Fig.1A and Fig.1E ). Comprehensive microbiological tests remained negative. For the next 40 days the patient remained hospitalized due to intermittent dyspnea, fever, asthenia, elevated markers of inflammation and received symptomatic therapy. 49 days after the initial onset of symptoms, her fever eventually subsided and the patient was again discharged (Fig.1A) . 5 days later, a scheduled outpatient followup appointment revealed a Hb of 7.2 mg/dl, progressive dyspnea and liquid diarrhea. After readmission to a local hospital, the patient received blood transfusions and antibiotic therapy but M a n u s c r i p t 4 remained febrile with hypotensive episodes (90/60 mm Hg) and was consecutively transferred to our hospital. SARS-CoV-2 PCR revealed viral RNA in the patients' blood and stool (Fig.1A) . IL-6 and CRP as well as proBNP were elevated (81.1 pg/ml, 198 mg/dl and 2250 ng/l respectively; Tab.1). T-cell counts further declined with a preferential loss of CD8+ cells, resulting in an elevated CD4 + /CD8 + Tcell ratio of 6.62. Transthoracic echocardiography revealed normal cardiac function. A pulmonary embolism was ruled out by CT-imaging which revealed progressive bi-pulmonary consolidations and ground glass opacities (Fig.1E ). 63 days after onset of symptoms, intravenous remdesivir treatment was initiated with a loading dose of 200 mg followed by nine days of 100 mg per day as part of the open-label GS-US-540-5773 trial. The fever quickly resolved and her cough and diarrhea improved. After ten days of remdesivir therapy no SARS-CoV-2-RNA was detectable in her blood and stool and inflammatory parameters normalized (Fig.1A, Tab.1) . A CT-scan showed regression of pulmonary infiltrates and the patient was discharged (Fig. 1E : Pictures G-I).

Eight days after cessation of treatment with remdesivir, fever, cough, diarrhea and asthenia reoccurred and the patient was readmitted to our hospital with detectable SARS-CoV-2-RNA in blood and sputum, as well as elevated inflammatory markers and again increased lymphocytopenia (Fig.1A , Tab.1). Under the impression of a recrudescence of COVID-19, including detectable SARS-CoV-2 viremia, and having ruled out other infectious complications, the patient received 100 mg remdesivir per day for five days within the framework of a compassionate use program. Again, symptoms rapidly improved. To prevent a second relapse in the absence of an intrinsic antibodyresponse it was then decided in agreement with the patient, to administer convalescent plasma therapy as an individual healing attempt. Two courses of six units of convalescent plasma were transfused, each consisting of 2 units per day administered every other day (Fig.1B) . Three weeks after the last plasma administration, the patient was asymptomatic and SARS-CoV-2 PCR from swabs and blood remained negative. Since then the patient has achieved a sustained control of viremia and has remained asymptomatic. Anti-SARS-CoV-2 IgG serum-concentrations were detectable directly after the transfusions but decreased over the following weeks (Fig.1B) .

Written informed consent was obtained from the patient. PCR to detect SARS-CoV-2 RNA and detection of specific antibodies were performed as described previously [8, 9] . 138 peptides overlapping by ten amino acids corresponding to the complete SARS-CoV-2 membrane-, envelope-, and nucleocapsid amino acid sequence were synthesized and pooled into 13 pools [9] . High definition human leukocyte antigen class I and II typing was performed by PCR-sequencespecific oligonucleotide probing. 30-50 x 10 6 fresh peripheral blood mononuclear cells were stimulated with one of the 13 peptide pools for 10 days. After 10 days, cells were re-stimulated with single SARS-CoV-2-peptides and subsequently assayed for interferon-γ production by Enzyme-linked immunosorbent spot and intracellular cytokine staining as previously described [9, 10] . M a n u s c r i p t 5

Anti-CD20 therapy has been reported to impair cytokine production, B-/T-cell interactions and to reduce cell populations including T-and B-memory cells [11] . Although production of immunoglobulins is not immediately impaired by obinutuzumab -since plasma-cells do not express CD20 -CD20-mediated depletion of earlier B-cell differentiation stages attenuates the humoral immune response to neoantigens [11] . In accordance with these observations our patient showed immunoglobulin levels at the lower limits of normal (Tab.1) and no SARS-CoV-2-specific antibodies were detectable prior to the treatment with convalescent plasma. While the virus was cleared from the upper airways within twenty days, the patient was unable to control SARS-CoV-2 viremia despite a broad SARS-CoV-2 T-cell response (Fig.1D) . CT-scans at days 35 and 62 revealed progressive lung infiltrations (Fig.1E) , and repeated SARS-CoV-2-specific PCR from sputum, blood and stool tested positive (Fig.1A ) -indicating first a shift from the upper to the lower airways and eventually dissemination of the virus to different body compartments. Unfortunately, routine blood and stool SARS-CoV-2 PCR testing became only available during the course of her hospitalization, and the kinetics of viral dissemination could not be determined. A reinfection with SARS-CoV-2 could be an alternative explanation of the reoccurrence of symptoms after the first course of remdesivir. However, the patient had stayed in strict home isolation after discharge and had repeated negative nasopharyngeal swabs after readmission (Fig.1A) . Therefore, the possibility of a reinfection was considered very unlikely.

Remdesivir shortens recovery time in immunocompetent patients, likely by inhibiting proliferation of viral RNA [7] . Efficacy data on convalescent plasma for treatment of COVID-19 are scarce but suggest an improved outcome in immunocompetent patients [12] . However, in this case the rationale for plasma administration was to substitute the specific antibodies that the patient was unable to produce herself.

While remdesivir did not appear to sufficiently suppress the viral replication on its own, the combination of remdesivir, followed by convalescent plasma therapy, coincided with a sustained virological response. After plasma transfusion, anti-SARS-CoV-2 IgG remained detectable in decreasing concentrations and were most probably transfused allogenic antibodies.

Whether plasma transfusion alone would have been sufficient to clear the virus can only be speculated. The overall efficacy of plasma therapy in viremic SARS-CoV-2 patients alone or in combination with other antivirals has not yet been reported. In this current case, the rationale of applying plasma therapy was to prevent another recrudescence of COVID-19 after remdesivir therapy in the absence of intrinsic SARS-CoV-2-antibodies.

It is not clear in how far patients lacking a B-cell response are protected from reinfection by their immune system. Also, it is unknown, whether and at which point a sustained viral response can be assumed in SARS-CoV-2 infections after therapy-induced clearance of the virus.

Successful treatment of SARS-CoV-2 infection in immunocompromised patients might require combined and prolonged antiviral treatment regimens that need to be established in future prospective trials that focus on this vulnerable patient population.

A c c e p t e d M a n u s c r i p t 6

The authors thank the UKE ID COVID-19 study team. They extend their gratitude to the patient for allowing us to report this interesting case. We thank Diana Brainard for critical discussions.

This work was supported by Deutsche Forschungsgemeinschaft (DFG) and German Center for Infection (DZIF). DFG SFB841 to JSzW, ML and SH, DFG SFB1328 to JSzW, FH and SH. nor  mal  rang  e   12  23  29  31  36  45  58  63  68  70  74  76  79  84  92  97  10  3  110  114  124 <35  16  22  38  20  44  26  45  43  60  50  33  25  29  29  48  54  48  40  34  30   AST, U/l  <35  27  29  39  31  38  28  73  38  77  50  37  31  32  52  62  69  44  32  36  21   Total 

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients

Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system

Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute Plasmodium falciparum Malaria

Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

A c c e p t e d M a n u s c r i p t